Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital.

Cunningham N, Shepherd S, Mohammed K, Lee KA, Allen M, Johnston S, Kipps E, McGrath S, Noble J, Parton M, Ring A, Turner NC, Okines AFC

Open source

DOI: 10.1007/s10549-022-06703-3
Published: 2022 Oct
Container: Breast cancer research and treatment
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10549-022-06703-3,
  title = {Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital.},
  author = {Cunningham N and Shepherd S and Mohammed K and Lee KA and Allen M and Johnston S and Kipps E and McGrath S and Noble J and Parton M and Ring A and Turner NC and Okines AFC},
  year = {2022},
  journal = {Breast cancer research and treatment},
  doi = {10.1007/s10549-022-06703-3},
  url = {https://doi.org/10.1007/s10549-022-06703-3}
}

RIS

TY  - JOUR
TI  - Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital.
AU  - Cunningham N
AU  - Shepherd S
AU  - Mohammed K
AU  - Lee KA
AU  - Allen M
AU  - Johnston S
AU  - Kipps E
AU  - McGrath S
AU  - Noble J
AU  - Parton M
AU  - Ring A
AU  - Turner NC
AU  - Okines AFC
PY  - 2022
JO  - Breast cancer research and treatment
DO  - 10.1007/s10549-022-06703-3
UR  - https://doi.org/10.1007/s10549-022-06703-3
ER  -

APA

N, C., S, S., K, M., KA, L., M, A., S, J., E, K., S, M., J, N., M, P., A, R., NC, T., & AFC, O. (2022). Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital.. Breast cancer research and treatment. https://doi.org/10.1007/s10549-022-06703-3

Source records

pubmed · retrieved 2026-09-26T11:40:55.770Z